GILD34:BVMF
Gilead Sciences Inc BDR
65,81 R$
0,00%
(0,00) 1D
16 okt, 16:56:00 GMT-3 · BRL
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoGILD34 üçün ən vacib statistik məlumatlar yaradılır...
Açın
66,36 R$
Yüksək
66,41 R$
Aşağı
65,81 R$
Bazar kapitalizasiyası
193,67 mlrd
Ortalama həcm
261,00
Həcm
1,78K
52 həftəlik ən yüksək
67,38 R$
52 həftəlik ən aşağı
51,33 R$
Dövriyyədəki səhmlər
1,24 mlrd
İşçilərin sayı
17K
Açın
66,36 R$
Yüksək
66,41 R$
Aşağı
65,81 R$
Bazar kapitalizasiyası
193,67 mlrd
Ortalama həcm
261,00
Həcm
1,78K
52 həftəlik ən yüksək
67,38 R$
52 həftəlik ən aşağı
51,33 R$
Dövriyyədəki səhmlər
1,24 mlrd
İşçilərin sayı
17K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
The Motley Fool
·
11 saat öncə
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
13 saat öncə
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
1 gün öncə
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
1 gün öncə
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences Inc BDR haqqında
Baş İcraçı DirektorDaniel O'Day
İşçilər17K
Təsis Tarixi22 iyn 1987
Baş OfisFoster City, Kaliforniya, Amerika Birləşmiş Ştatları
Sektor-
Veb-saytgilead.com